Abstract 1194P
Background
Artificial intelligence (AI) based on deep learning and convolutional neural networks (CNN) has been applied to various medical fields. We are developing a novel AI system to support the detection of lung cancer, which will enable physicians to efficiently interpret radiograms and perform diagnosis.
Methods
For training data, we analyzed the image features of 800 chest X-ray images (acquired mainly for lung cancer screening; 400 normal images and 400 abnormal images) from Fukushima Preservative Service Association of Health and 5 000 chest radiographs from the National Institutes of Health (NIH) database. We categorized these data into two groups. Group A included both 800 images and NIH database, and group B included only 800 images. Then, using ImageNet, we used these datasets to develop a proprietary AI algorithm with deep learning and a CNN, and analyzed the statistical accuracy of interpretations of the radiograms. We also demonstrated abnormal shadow in the form of a heat map display on each chest radiograph for easy visualization, and presented the positive probability score as an index value from 0.0 to 1.0 indicating the possibility of lung cancer. The accuracy of our AI system was improved by using technology to account for differences in radiographic apparatus and imaging environments.
Results
Using a positive probability cutoff value of 0.5, our novel AI showed an area under the curve (AUC) of 0.74, sensitivity of 0.75, and specificity of 0.60 for group A, and AUC of 0.79, sensitivity of 0.72, and specificity of 0.74 for group B. The accuracy on both groups was superior to that of radiologists (AUC 0.72), and was also compatible with previous study reports (AUC 0.67-0.78). The number of training data did not make a difference in accuracy. The heat map display was also clearly demonstrated on the monitor screen if a roentgenogram had abnormal shadows.
Conclusions
In this study, we confirmed that our proprietary AI system had a similar accuracy in the interpretation of chest radiographs to that of previous studies and radiologists. However, further research and improvement is needed to verify the accuracy. We are now in the process of performing various types of validation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Grants-in-Aid for Scientific Research in Japan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Lung cancer scRNA-seq analyses reveal potential mechanisms causing different efficacy of target therapy and immunotherapy between EGFR 19del and L858R lung adenocarcinoma
Presenter: Hao Wang
Session: Poster session 09
225P - Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
Presenter: Junko Tanizaki
Session: Poster session 09
226TiP - CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma
Presenter: Erick Saldanha
Session: Poster session 09
227TiP - A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 09
228TiP - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs
Presenter: Mika Mustonen
Session: Poster session 09
229TiP - A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
Presenter: Robert Walsh
Session: Poster session 09
230TiP - Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program
Presenter: Beatriz Alonso de Castro
Session: Poster session 09
694P - Sequential high-dose-chemotherapy with 4 cycles paclitaxel, ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory male germ cell cancer: Final results with 15.8 years follow-up
Presenter: Hans Joachim Schmoll
Session: Poster session 09
695P - Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
Presenter: Deep Chakrabarti
Session: Poster session 09
696P - Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma
Presenter: David Pfister
Session: Poster session 09